Introduction
While there are many toxins present in the environment, none is as pervasive as arsenic. In fact, the 2013 Environmental Protection Agency's Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) Priority List of Hazardous Substances ranks arsenic first based on a combination of its frequency, toxicity and potential for human exposure (http://www.atsdr.cdc.gov/spl/). The widespread impact of arsenic toxicity can be attributed to the ubiquity of arsenic in the environment (Zhu et al., 2014) . Natural sources of arsenic include soil, water and food supplies. Arsenic consumption from foods such as meats, vegetables and fish has been linked to skin, bladder and lung cancer (Oberoi et al., 2014) . Genes for arsenic(III) S-adenosylmethionine (SAM) methyltransferases are widespread in the genomes of bacteria, archaea, fungi, lower plants and animals, including humans. In microbes, the ArsM (arsenite S-adenosylmethyltransferase) orthologs detoxify arsenic (Qin et al., 2006 (Qin et al., , 2009 . In contrast, the health effects of arsenic may be attributed to the methylation of inorganic arsenic by the human ortholog, hAS3MT, which catalyzes the biotransformation of arsenic(III), primarily in the liver, to methylated products that are more toxic and carcinogenic in humans (Thomas & Rosen, 2013; Thomas et al., 2004 Thomas et al., , 2007 .
Structural data from the CmArsM enzyme of the eukaryotic acidothermophilic red alga Cyanidioschyzon merolae have shed light on the functional aspects of human hAS3MT (Ajees et al., 2012) . However, a more complete understanding of the relationship of this family of enzymes to arsenic carcinogenesis would be aided by additional crystal structures from other orthologs. Comparison of the structures of orthologs will illuminate which domains and residues may be functionally significant. CrArsM from the eukaryotic green alga Chlamydomonas reinhardtii (JX480492.2) catalyzes arsenic methylation and volatilization, leading to arsenic resistance (Chen et al., 2013) . The gene for CrArsM, a 379-residue enzyme (41.6 kDa), was synthesized and expressed in Escherichia coli. Here, we report the crystallization, X-ray data collection and preliminary crystallographic analysis of CrArsM.
Materials and methods

Reagents
All chemicals were obtained from Sigma-Aldrich (St Louis, Missouri, USA) unless otherwise mentioned.
Cloning, expression and purification of CrArsM
The native CrArsM gene (accession No. JX480492.2) was expressed and purified as described by Chen et al. (2013) . However, we were unable to crystallize the purified protein. For this reason, a CrArsM gene was designed based on the native gene, with NcoI and XhoI restriction sites flanking the 5 0 and 3 0 ends of the gene, respectively. The gene was chemically synthesized by GenScript USA Inc. (New Jersey) and inserted into vector plasmid pUC57 (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The sequence of the gene was optimized by GenScript using their OptimumGene algorithm, which improves expression by analyzing and upgrading the codon-adaptation index (Sharp & Li, 1987) , modifying the GC content and disrupting stem-loop structures that affect the ribosome binding and the stability of the mRNA ( Supplementary Fig. S1a 1 ) . Native CrArsM has 17 cysteine residues, of which four are conserved in orthologs. Multiple cysteine residues may interfere with crystallization, and alanine substitutions can produce a more tractable protein with improved storage properties (Hari et al., 2010) . For this reason, the four conserved cysteine residues at the conserved positions 46, 74, 170 and 220 were retained, while the other 13 cysteine residues were changed to alanine residues. Trp332 and Tyr72 of the native CrArsM protein were mutated to tyrosine and tryptophan residues, respectively, in the synthetic CrArsM for future measurements of ligand binding by changes in intrinsic tryptophan fluorescence. Otherwise, the sequence of the synthetic protein was the same as native CrArsM ( Supplementary Fig. S1b ). The gene was cloned into vector plasmid pET-29b(+) (EMD Biosciences, California, USA) as an NcoI/XhoI digest, generating plasmid pET29-CrArsM in which the CrArsM gene is under the control of the T7 promoter and is expressed with a six-histidine tag at the C-terminus.
Cells of E. coli strain BL21(DE3) pET29-CrArsM were grown at 37 C in Luria-Bertani medium (Sambrook et al., 1989) containing 50 mg ml À1 kanamycin with shaking at 240 rev min À1 . When the absorbance at 600 nm of the culture reached 0.6, 0.1 mM isopropyl -d-1-thiogalactopyranoside (IPTG; Research Products International, Mount Prospect, Illinois, USA) was added to induce expression of CrArsM. The cells were grown for a further 4 h, harvested by centrifugation (3500g) for 30 min, washed once with buffer A [50 mM MOPS pH 7.5, 0.5 M NaCl containing 20%(w/v) glycerol, 20 mM imidazole and 10 mM -mercaptoethanol] and suspended in 5 ml buffer A per gram of wet cells. The cells were lysed by two passes through a French pressure cell press at 138 MPa and immediately treated with 2.5 ml of the protease inhibitor diisopropyl fluorophosphate per gram of wet cells. Membranes and unbroken cells were removed by centrifugation at 150 000g for 1 h (Qin et al., 2006) and the supernatant solution was loaded at a flow rate of 0.5 ml min À1 onto a 5 ml HisTrap HP column (GE Healthcare) pre-equilibrated with buffer A using an Ä KTA FPLC purification system (GE Healthcare). The column was washed with five column volumes of buffer A followed by elution with five column volumes of buffer A containing 0.2 M imidazole. Purified synthetic CrArsM was identified by SDS-PAGE (Laemmli, 1970;  Fig. 1, lane 2) . The migration of the band corresponded to the mass of CrArsM. Fractions containing CrArsM were concentrated by centrifugation using a 10 kDa cutoff Amicon Ultrafilter (EMD Millipore Corporation, Billerica, Massachusetts, USA) and were buffer-exchanged with buffer C consisting of 50 mM MOPS pH 7.5, 0.5 M NaCl, 5 mM dithiothreitol (DTT), 2.5 mM ethylenediamine tetraacetate, 10%(w/v) glycerol for storage at À80 C until use. The yield was 23 mg of purified protein from 1 l of cell culture.
Crystallization
The purified CrArsM was buffer-exchanged into a buffer consisting of 50 mM MOPS pH 7.0, 0.5 M NaCl, 5 mM DTT. Initial crystallization trials were performed by the hanging-drop vapor-diffusion method using crystallization screens from Hampton Research (Aliso Viejo, California, USA), Emerald Bio (Bainbridge Island, Washington, USA) and Jena Biosciences GmbH (Jena, Germany).
At 18 and 20 C, crystallization trials produced crystalline aggregates upon mixing 2.0 ml each of protein and reservoir (20% PEG 3350, 0.2 M calcium acetate, 0.1 M Tris-HCl pH 7.0) solutions. Reduction of the PEG concentration from 20 to 18% led to the formation of needle-like crystals that were used for seeding experiments. The needles were transferred from the hanging drop to eppendorf tubes containing seed beads (Hampton Research) and 0.1 ml well solution. Sample preparation for seeding was as described previously (Marapakala et al., 2010) . Diffraction-quality crystals (Fig. 2) were obtained at room temperature using Linbro 24-well plates (Hampton Research). The wells, sealed with a cover slip, held 0.5 ml of seed stock (1:100 ratio) in drops consisting of equal volumes of protein and reservoir (10% PEG 8000, 2.0 M NaCl) solutions. The crystals from a single drop were washed several times in 50% glycerol and dissolved in water for analysis by SDS-PAGE (Fig. 1, lane 1) .
Data collection and processing
Crystals were transferred to a cryoprotectant solution (10% PEG 8000, 2.0 M NaCl, 20% 2-methyl-2,4-pentanediol) and flash-cooled in liquid nitrogen for data collection. Initial crystals were screened at CrArsM was purified by Ni-NTA chromatography as described in x2.1. The purity of the protein was analyzed by SDS-PAGE stained with Coomassie Blue. Lane 1, a single crystal of CrArsM dissolved in water. Lane 2, purified and concentrated CrArsM from Ni-NTA chromatography. Lane 3, molecular-weight markers (labelled in kDa). The position of CrArsM is indicated by an arrow.
the Advanced Light Source, Berkeley Center for Structural Biology. Subsequent data sets were collected at the Southeast Regional Collaborative Access Team (SER-CAT) facility at the Advanced Photon Source (APS), Argonne, Illinois, USA. Data were obtained from 360 image frames with a 1 rotation angle about ' using a MAR 225 CCD detector under standard cryogenic conditions (À173 C) on synchrotron beamline 22-BM with a crystal-to-detector distance of 240 mm. The data sets were indexed, integrated and scaled with the HKL-2000 suite (Otwinowski & Minor, 1997) . The data-processing statistics are shown in Table 1 .
Results and discussion
Needle-shaped crystals of CrArsM initially diffracted to a resolution in the range 7.0-4.5 Å , but improved with seeding. Diffraction-quality crystals formed overnight with dimensions 0.3 Â 0.3 Â 0.2 mm. The crystals were stable for at least one week, after which they began to dissolve. Complete data sets were collected to 2.40 Å resolution from a single crystal of CrArsM (Fig. 3) . The crystals belonged to space group R3:H, with unit-cell parameters a = b = 157.8, c = 95.4 Å , = 120 . Evaluation of crystal-packing parameters indicated that the lattice can accommodate two molecules in the asymmetric unit, with a Matthews coefficient of 2.73 Å 3 Da À1 and a solvent content of 54.9%. The sequence similarity between CmArsM and CrArsM is 44.0%, so we attempted to use the native X-ray crystal structure of CmArsM (PDB entry 4fs8; Ajees et al., 2012) to solve the structure of CrArsM by molecular replacement, without success. To solve the phase problem, attempts to obtain crystals of CrArsM co-crystallized or soaked with heavy metals are in progress. 
Figure 3
Diffraction images (1 oscillation) were collected from CrArsM crystals at APS (Advanced Photon Source) using a MAR 300 detector at À173 C. The edge of the image corresponds to 2.40 Å resolution. 
